Early menopause is a $56.7 billion problem for 17.2 million women in US. With the yearly costs of $429 million for 130,000 women.
Early menopause is a $56.7 billion problem for 17.2 million women in US. With the yearly costs of $429 million for 130,000 women.
This is a conservative estimate. Let us show you.
We measured the health and economic impact of a 5-year therapeutic delay for menopause in women before 45 in US.
This is a conservative estimate. Let us show you.
We measured the health and economic impact of a 5-year therapeutic delay for menopause in women before 45 in US.
Health Impact
Up to 10% of women have menopause before 45.
(Anagnostis et al., 2025)
Up to 10% of women have menopause before 45.
(Anagnostis et al., 2025)
Up to 10% of women have menopause before 45.
(Anagnostis et al., 2025)
Earlier menopause is linked with a higher risk for all-cause mortality and various diseases.
Earlier menopause is linked with a higher risk for all-cause mortality and various diseases.
Earlier menopause is linked with a higher risk for all-cause mortality and various diseases.
Cardiovascular disease, type 2 diabetes, dementia, osteoporosis and so on.
Cardiovascular disease, type 2 diabetes, dementia, osteoporosis and so on.
Cardiovascular disease, type 2 diabetes, dementia, osteoporosis and so on.
The yearly impact of a 5-year therapeatic delay per 100,000 cases would be:
The yearly impact of a 5-year therapeatic delay per 100,000 cases would be:
The yearly impact of a 5-year therapeatic delay per 100,000 cases would be:
-0
-0
Deaths
-0
-0
Deaths
-0
-0
Deaths
-0
-0
Type 2 Diabetics
-0
-0
Type 2 Diabetics
-0
-0
Type 2 Diabetics
-0
-0
Cardiovascular Diseases
-0
-0
Cardiovascular Diseases
-0
-0
Cardiovascular Diseases
-0
-0
All Cause Dementias
-0
-0
All Cause Dementias
-0
-0
All Cause Dementias
-0
-0
Osteoporosis & Fractures
-0
-0
Osteoporosis & Fractures
-0
-0
Osteoporosis & Fractures
+0
+0
New breast cancers
+0
+0
New breast cancers
+0
+0
New breast cancers
+0
+0
Endometrial Cancers
+0
+0
Endometrial Cancers
+0
+0
Endometrial Cancers
+0
+0
Ovarian Cancers
+0
+0
Ovarian Cancers
+0
+0
Ovarian Cancers
Economic Impact
From these numbers we can derive direct and indirect costs for the 130,000 women expected to reach menopause before 45 each year.
$83,943,000: Yearly Direct Costs
Medical bills, treatment facilities and so on.
$83,943,000: Yearly Direct Costs
Medical bills, treatment facilities and so on.
$83,943,000: Yearly Direct Costs
Medical bills, treatment facilities and so on.
$345,658,000: Yearly Indirect Costs
Lost productivity, absenteeism, and unpaid caregiving.
$345,658,000: Yearly Indirect Costs
Lost productivity, absenteeism, and unpaid caregiving.
$345,658,000: Yearly Indirect Costs
Lost productivity, absenteeism, and unpaid caregiving.
$429,601,000: Yearly Total Costs
Summing up direct and indirect cost. Can be seen as yearly addressable market.
$429,601,000: Yearly Total Costs
Summing up direct and indirect cost. Can be seen as yearly addressable market.
$429,601,000: Yearly Total Costs
Summing up direct and indirect cost. Can be seen as yearly addressable market.
$56,764,543,000: Total Addressable Market
Total costs when scaled to all 17.2 million women in US that experienced menopause before 45.
$56,764,543,000: Total Addressable Market
Total costs when scaled to all 17.2 million women in US that experienced menopause before 45.
$56,764,543,000: Total Addressable Market
Total costs when scaled to all 17.2 million women in US that experienced menopause before 45.
These numbers are conservative.
They exclude women reaching menopause between 45 and 50.
This group also faces elevated health risks.
Millions more could be affected.
These numbers are conservative.
They exclude women reaching menopause between 45 and 50.
This group also faces elevated health risks.
Millions more could be affected.
These numbers are conservative.
They exclude women reaching menopause between 45 and 50.
This group also faces elevated health risks.
Millions more could be affected.
Methodology
Report
Our comprehensive report documents the full methodology behind our economic analysis. It includes information about the autonomous AI pipeline used for literature review, the detailed calculations for both direct and indirect costs, and complete citations backing every figure used in our estimates.
Code
To speed up and improve the quality of our literature review, we deployed an AI agent. Running for more than 5 hours, this agent read through 1,655 meta-analyses, extracting 584 risk metrics. The full code and a CSV file containing all 584 risk metrics, along with their citations and metadata, can be found in our open-source GitHub repository.
Report
Our comprehensive report documents the full methodology behind our economic analysis. It includes information about the autonomous AI pipeline used for literature review, the detailed calculations for both direct and indirect costs, and complete citations backing every figure used in our estimates.
Code
To speed up and improve the quality of our literature review, we deployed an AI agent. Running for more than 5 hours, this agent read through 1,655 meta-analyses, extracting 584 risk metrics. The full code and a CSV file containing all 584 risk metrics, along with their citations and metadata, can be found in our open-source GitHub repository.
Report
Our comprehensive report documents the full methodology behind our economic analysis. It includes information about the autonomous AI pipeline used for literature review, the detailed calculations for both direct and indirect costs, and complete citations backing every figure used in our estimates.
Code
To speed up and improve the quality of our literature review, we deployed an AI agent. Running for more than 5 hours, this agent read through 1,655 meta-analyses, extracting 584 risk metrics. The full code and a CSV file containing all 584 risk metrics, along with their citations and metadata, can be found in our open-source GitHub repository.
Authors
Methodology
Mark Kagach
Methodology
Mark Kagach
Methodology
Mark Kagach
Code
Elias Schlie
Code
Elias Schlie
Code